Table 1.
Sample panels used in the study.
Table 2.
List of ZIKV IgM and IgG serologic assays evaluated.
Fig 1.
(A) Sensitivity and specificity of ZIKV IgM rapid ICT, ELISAs and IIFT using acute samples from ZIKV-confirmed, DENV-confirmed, and non-ZIKV and non-DENV patients (Set A; n = 78). Sensitivity and specificity of ZIKV IgM/IgG rapid ICT, IgM ELISAs/IIFT and IgG ELISAs using (B) 7–14 days’ (Set B1; n = 57) and (C) 23–34 days’ (Set B2; n = 64) convalescent samples from ZIKV-confirmed, DENV-confirmed, and non-DENV patients. Confidence intervals (black bars) were constructed using Wald’s method.
Table 3.
Test performance characteristics (AUROCC) in acute and convalescent patient samples.
Fig 2.
(A) Specificity of ZIKV IgM rapid ICT, ELISAs and IIFT using acute samples from DENV-confirmed (n = 30), and non-ZIKV and non-DENV (n = 30) patients. (B) Specificity of ZIKV IgM/IgG rapid ICT, IgM ELISAs/IIFT and IgG ELISAs using 7–34 days’ convalescent samples from DENV-confirmed (n = 30), and non-DENV patients (n = 30) (Set B). Confidence intervals (black bars) were constructed using Wald’s method. LumiQuick QuickProfile™ ZIKV IgM & IgG rapid ICTs refer to a combo test kit.
Table 4.
Results of ZIKV IgG ELISA using healthy blood donor samples.
Table 5.
ZIKV seropositivity in convalescent primary and secondary DENV patient samples.